This article looks at the potential use of CBD oil as a primary treatment for lung cancer, based off a case study of an individual who declined conventional treatment for non-small cell lung cancer (NSCLC).
The patient, a woman in her 80’s, was diagnosed with lung cancer in 2018 after observation of a 41mm lesion in the right middle lobe of her lung, and despite declining treatment, regular CT scans in 3-6 month intervals over a 2.5 year period showed the initial 41mm lesion had reduced to 10mm, representing an overall 76% reduction in axial diameter.
Sativa Wellness Group (AQSE:SWEL) goal is to be recognised as one of the leading health companies, through building the best wellness brands in CBD testing services and products, to meet today’s fast evolving consumer expectations. Through full vertical integration of their supply chain and expansion of their distribution network, they plan to become one of the premier producers and high-quality distributors of CBD and wellness products and services in Europe.
